'What Else Don't We Know?' May Spread Beyond Valeant
This article was originally published in Scrip
The day after a damning report from short-selling firm Citron Research sent shares of Valeant Pharmaceuticals International Inc. into tailspin, diving 40%, the stock spiraled down again, plunging 20% – this time pushed off the cliff by BMO Nesbitt Burns Inc. analyst Alex Arfaei, who started off the day by asking "What else is out there that we don't know?"
Register for our free email digests: